Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» July 2011
July 2011
Chelsea Therapeutics: Likely to Double on Safe, Proven Asset
Chelsea Therapeutics: Likely to Double on Safe, Proven Asset
Seeking Alpha
Chelsea Therapeutics
Droxidopa
CH-4051
Another Day, Another Loss For Cell Therapeutics
Another Day, Another Loss For Cell Therapeutics
Motley Fool
Cell Therapeutics
Vertex Pharmaceuticals Beats Merck in Hepatitis C Drug Sales
Vertex Pharmaceuticals Beats Merck in Hepatitis C Drug Sales
Bloomberg
Vertex Pharmaceuticals
Merck
Incivek
Victrelis
hepatitis C
Affymetrix Cuts Losses in 2Q
Affymetrix Cuts Losses in 2Q
Yahoo/Zacks
Affymetrix
earnings
StemCells Reports a Q2 Net Loss of $4M or $0.29 per share
StemCells Reports a Q2 Net Loss of $4M or $0.29 per share
Seeking Alpha
StemCells
earnings
4 Biotech Companies Reporting Earnings Next Week With Recent Winning Streaks
4 Biotech Companies Reporting Earnings Next Week With Recent Winning Streaks
Seeking Alpha
Ariad Pharmaceuticals
NPS Pharmaceuticals
Immunogen
Alnylam
Vertex advances 8% on earnings, upgrade
Vertex advances 8% on earnings, upgrade
MarketWatch
Vertex Pharmaceuticals
PPDI Beats Overall
PPDI Beats Overall
Yahoo/Zacks
PPDI
earnings
Jazz Pharmaceuticals Shares Popped: What You Need to Know
Jazz Pharmaceuticals Shares Popped: What You Need to Know
Motley Fool
Jazz Pharmaceuticals
Revenues Rise at BioMarin
Revenues Rise at BioMarin
Yahoo/Zacks
Biomarin
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »